Know Cancer

or
forgot password

Interlaboratory Comparability Study of Residual Disease in Acute Myelogenous Leukemia


N/A
N/A
N/A
Open (Enrolling)
Both
Leukemia

Thank you

Trial Information

Interlaboratory Comparability Study of Residual Disease in Acute Myelogenous Leukemia


OBJECTIVES:

- To promote harmonization between Cooperative Group Reference Laboratories conducting
minimal-residual disease (MRD) evaluation of acute myeloid leukemia by flow cytometry.

OUTLINE: Archived bone marrow and blood samples, distributed to the Eastern Cooperative
Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B laboratories, are
analyzed for leukemia-associated immunophenotype (LAIP) assays and minimal residual disease
studies by flow cytometry. Results are then provided to the National Cancer Institute for
assessment and comparability of test results.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Non-identified cryopreserved samples of bone marrow and/or peripheral blood from
patients with acute myeloid leukemia (AML) from the Children Oncology Group (COG)
studies

- Baseline/diagnostic AML samples

- Samples collected after initial treatment and representing varying levels of
residual blast counts

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Not specified

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Degree of concordance in the MRD assay results between laboratories

Safety Issue:

No

Principal Investigator

J. Milburn Jessup, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Cancer Institute (NCI)

Authority:

United States: Federal Government

Study ID:

CDR0000720362

NCT ID:

NCT01498302

Start Date:

February 2012

Completion Date:

Related Keywords:

  • Leukemia
  • childhood acute myeloid leukemia/other myeloid malignancies
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid
  • Neoplasm, Residual

Name

Location